TITLE

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

AUTHOR(S)
Lassen, Amanda; Atefi, Mohammad; Robert, Lidia; Wong, Deborah; Cerniglia, Michael; Comin-Anduix, Begonya; Ribas, Antoni
PUB. DATE
April 2014
SOURCE
Molecular Cancer;2014, Vol. 13 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance. In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway can prevent emergence of resistance or provide additional growth inhibitory effects in vitro. Methods Anti-tumor effects of the combination of the BRAF inhibitor (BRAFi) dabrafenib and GSK2141795B (AKTi) in a panel of 23 BRAF mutated melanoma cell lines were evaluated on growth inhibition by an ATP-based luminescent assay, on cell cycle and apoptosis by flow cytometry and on cell signaling by western blot. Moreover, we investigated the possibilities of delaying or reversing resistance or achieving further growth inhibition by combining AKTi with dabrafenib and/or the MEK inhibitor (MEKi) trametinib by using long term cultures. Results More than 40% of the cell lines, including PTEN-/- and AKT mutants showed sensitivity to AKTi (IC50 < 1.5 µM). The combination of dabrafenib and AKTi synergistically potentiated growth inhibition in the majority of cell lines with IC50 > 5 nM dabrafenib. Combinatorial treatment induced apoptosis only in cell lines sensitive to AKTi. In long term cultures of a PTEN-/- cell line, combinatorial treatment with the MAPK inhibitors, dabrafenib and trametinib, and AKTi markedly delayed the emergence of drug resistance. Moreover, combining AKTi with the MAPK inhibitors from the beginning provided superior growth inhibitory effects compared to addition of AKTi upon development of resistance to MAPK inhibitors in this particular cell line. Conclusions AKTi combined with BRAFi-based therapy may benefit patients with tumors harboring BRAF mutations and particularly PTEN deletions or AKT mutations.
ACCESSION #
95641652

 

Related Articles

  • Microenvironment-mediated resistance to anticancer therapies. Olson, Oakley C; Joyce, Johanna A // Cell Research;Feb2013, Vol. 23 Issue 2, p179 

    Resistance to molecularly targeted therapies can result from genomic alterations in the tumor cells that reactivate oncogenic signaling. Less is known of tumor cell-extrinsic mechanisms of resistance to targeted therapies. Two recent studies have identified HGF as a soluble factor capable of...

  • WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. Anastas, Jamie N.; Kulikauskas, Rima M.; Tamir, Tigist; Rizos, Helen; Long, Georgina V.; von Euw, Erika M.; Pei-Tzu Yang; Hsiao-Wang Chen; Haydu, Lauren; Toroni, Rachel A.; Lucero, Olivia M.; Chien, Andy J.; Moon, Randall T. // Journal of Clinical Investigation;Jul2014, Vol. 124 Issue 7, p2877 

    About half of all melanomas harbor a mutation that results in a constitutively active BRAF kinase mutant (BRAFV600E/K) that can be selectively inhibited by targeted BRAF inhibitors (BFLAFis). While patients treated with BRAFis initially exhibit measurable clinical improvement, the majority of...

  • AKT-ing out: SGK kinases come to the fore. MONIZ, Larissa S.; VANHAESEBROECK, Bart // Biochemical Journal;6/15/2013, Vol. 452 Issue 3, p11 

    The success of targeted therapies in treating cancer over the last decade has been tempered by acquired drug resistance that follows long-term treatment. There is also emerging evidence for innate mechanisms of cancer cell resistance to targeted therapy that preexist as parallel signalling...

  • Canonical Wnt Pathway Inhibitor ICG-001 Induces Cytotoxicity of Multiple Myeloma Cells in Wnt-Independent Manner. Grigson, Eileen R.; Ozerova, Maria; Pisklakova, Alexandra; Liu, Hao; Sullivan, Daniel M.; Nefedova, Yulia // PLoS ONE;Jan2015, Vol. 10 Issue 1, p1 

    Canonical Wnt signaling has been implicated in the regulation of multiple myeloma (MM) growth. Here, we investigated whether the targeting of this pathway with a novel pharmacological inhibitor ICG-001 would result in an anti-tumor effect and improvement of chemosensitivity in MM. As expected,...

  • Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. Can Liu; Yan Zeng; Long-Hai Dai; Tian-Yu Cai; Yue-Ming Zhu; De-Quan Dou; Lan-Qing Ma; Yuan-Xia Sun // American Journal of Cancer Research;2015, Vol. 5 Issue 4, p1308 

    Unlike solid tumors, the primary strategy for leukemia treatment is chemotherapy. However, leukemia chemotherapy is associated with adverse drug effects and drug resistance. Therefore, it is imperative to identify novel agents that effectively treat leukemia while minimizing adverse effects. The...

  • cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. Manfè, Valentina; Biskup, Edyta; Willumsgaard, Ayalah; Skov, Anne Guldhammer; Palmieri, Dario; Gasparini, Pierluigi; Laganá, Alessandro; Woetmann, Anders; Ødum, Niels; Croce, Carlo Maria; Gniadecki, Robert // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Successful/effective cancer therapy in low grade lymphoma is often hampered by cell resistance to anti-neoplastic agents. The crucial mechanisms responsible for this phenomenon are poorly understood. Overcoming resistance of tumor cells to anticancer agents, such as proteasome inhibitors, could...

  • CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. Ye Chen; Jacamo, Rodrigo; Konopleva, Marina; Garzon, Ramiro; Croce, Carlo; Andreeff, Michael // Journal of Clinical Investigation;Jun2013, Vol. 123 Issue 6, p2395 

    We examined the role of microRNAs (miRNAs) in targeting the stromal-derived factor la/CXCR4 (SDF-la/CXCR4) axis to overcome chemoresistance of AML cells. Microarray analysis of OCI-AML3 cells revealed that the miRNA let-7a was downregulated by SDF-la-mediated CXCR4 activation and increased by...

  • Trametinib.  // Reactions Weekly;Jun2015, Vol. 1555 Issue 1, p195 

    The article presents a case report of a 43-year-old man who developed resistance to trametinib being used to treat his melanoma.

  • Evodiamine Synergizes with Doxorubicin in the Treatment of Chemoresistant Human Breast Cancer without Inhibiting P-Glycoprotein. Wang, Shengpeng; Wang, Lu; Shi, Zhi; Zhong, Zhangfeng; Chen, Meiwan; Wang, Yitao // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Drug resistance is one of the main hurdles for the successful treatment of breast cancer. The synchronous targeting of apoptosis resistance and survival signal transduction pathways may be a promising approach to overcome drug resistance. In this study, we determined that evodiamine (EVO), a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics